The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. The goal is to stimulate a T cell immune response that eliminates tumor cells.
The study consists of two components: an initial phase I safety study to confirm safety/tolerability of the treatment regimen, and, subsequently, a single-arm phase II cohort to assess efficacy of the treatment regimen.
All participants will:
* Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection
* Receive two doses of DOC1021 under image guidance 2 weeks apart
* Receive subcutaneous pIFN injections weekly for a total of 4 doses in parallel with the DOC1021 injections
* Undergo an optional image-guided perinodal DOC1021 booster injection approximately 6 months after the first DOC1021 dose along with additional subcutaneous pIFN injections at time of the booster and the subsequent week for a total of 2 pIFN doses
* Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive optional treatment with anti-PD1 agents

Start Date23 Feb 2026

Sponsor / Collaborator

Diakonos Oncology Corp.

NCT07135349

/ Active, not recruitingPhase 2

A Multi-center, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of BW-20507 Injection Combined With Pegylated Interferon Alfa in Patients With Chronic Hepatitis B Infection

This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients

Start Date02 Sep 2025

Sponsor / Collaborator

Shanghai Argo Biopharma Co., Ltd.

NCT06092333

/ RecruitingPhase 2IIT

A Pilot Study of the Combination of VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Background:
Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide; 887,000 die each year from cirrhosis, liver cancer, and related issues. Treatment options are limited.
Objective:
To test 2 drugs (VIR-2218 and peginterferon) in people with mild or inactive HBV infection.
Eligibility:
People aged 18 to 65 years with mild or inactive HBV infection.
Design:
Participants will be screened. They will have blood tests and an eye exam. They will have imaging scans of the liver to check the health of the liver.
Participants will be in the study for over 2 years.
VIR-2218 is an injection given under the skin of the stomach, upper arm, or thigh. Participants will come to the clinic to receive this injection once a month for 6 months.
Peginterferon is also injected under the skin. Participants will have this shot once a week for 6 months. They may either inject themselves at home or come to the clinic to get the injections.
Participants will get just the VIR-2218 for 3 months, then both shots for 3 months, then just the peginterferon for 3 months.
Participants will have two 3-day stays in the hospital. Tests will include:
Liver biopsy. A sample of tissue will be taken from their liver. After the procedure, participants will lie on their right side for 2 hours and then on their back for 4 hours.
Fine needle aspiration. A small needle will be used to collect cells from the liver.
After the last injection of peginterferon, follow-up visits will continue in the outpatient clinic every 4 to 12 weeks.

Start Date31 Jan 2025

Sponsor / Collaborator

National Institute of Diabetes & Digestive & Kidney Diseases

100 Clinical Results associated with Peginterferon alfa-2a

100 Translational Medicine associated with Peginterferon alfa-2a

100 Patents (Medical) associated with Peginterferon alfa-2a

3,874

Literatures (Medical) associated with Peginterferon alfa-2a

01 Feb 2026·CLINICA CHIMICA ACTA

Quantification of plasma mutant calreticulin for diagnosis and therapeutic response assessment of peginterferon-α in myeloproliferative neoplasms: A proof-of-concept study

Article

Author: Tian, Jingjing ; Tang, Gusheng ; Wu, Zhiyuan ; Zhou, Weiyan ; Yang, Can ; Ma, Xiaotong ; Wu, Quanli ; Tang, Xuemei ; Zhang, Qingyun ; Guan, Ming

BACKGROUND:

Calreticulin (CALR) exon 9 mutations are drivers in essential thrombocythemia (ET) and primary myelofibrosis (PMF). These mutations lead to extracellular secretion of mutant CALR, but a quantitative plasma assay to leverage this for management is lacking.

OBJECTIVE:

To develop and validate a quantitative method based on homemade monoclonal antibody (McAb) targeting mutant CALR for diagnosing ET and PMF, and evaluating therapeutic response in PEG-IFN-α-treated ET patients.

METHODS:

We generated a hybridoma clone (Cal26B11) producing anti-mutant CALR McAb and confirmed its reactivity via Western blot, immunofluorescence, and immunohistochemistry. Using Cal26B11 as the capture antibody, we developed a double-antibody sandwich ELISA (DAS-ELISA) to quantify plasma CALR mutant (pCALRmut). We assessed its diagnostic performance in 135 subjects (53 CALR type-1, and 37 type-2 mutant MPN patients, 11 non-CALR-mutated MPN patients, 9 non-MPN hematological malignancies, and 25 healthy donors) and conducted a 2-year follow-up of 49 CALR-mutant ET patients to evaluate its correlation with therapeutic response.

RESULTS:

Cal26B11 McAb showed high affinity (Kd = 5.90 × 10^-10 M) and specificity for mutant CALR proteins. The established DAS-ELISA demonstrated good linearity (6.25-200 ng/ml) and sensitivity (LOQ: 7.78 ng/mL for type-1; 9.82 ng/ml for type-2 mutants). Using a cut-off of 15.98 ng/mL, the assay discriminated CALR-mutant from wild-type cases with 96.67 % sensitivity and 100 % specificity. Baseline pCALRmut concentrations rose step-wise from ET to pre-fibrotic MF and overt MF (P < 0.0001). Although cross-sectional pCALRmut-VAF was weak, strong within-individual correlations during follow-up highlight its utility for serial monitoring. In patients treated with PEG-IFN-α, pCALRmut decreased in 76.5 % of cases, with a median reduction of 23.04 %, accompanied by a medium-to-long term complete hematological response (CHR) rate of approximately 75 %. Consistently, patients achieving CHR exhibited significantly lower pCALRmut levels than non-CHRs after PEG-IFN-α treatment, demonstrating a correlation between its dynamic reduction and treatment response.

CONCLUSIONS:

The Cal26B11-based DAS-ELISA provides a reliable, non-invasive tool for detecting CALR mutations and shows promise for monitoring disease dynamics and treatment response, supporting its potential as a complementary biomarker. These preliminary findings warrant validation in larger prospective studies.

01 Feb 2026·Innere Medizin (Heidelberg, Germany)

Article

Author: Hartung, W ; Lehringer-Polzin, M ; Brossmann, C ; Fleck, M ; Anagnostopoulos, I ; Glück, C ; Glück, Thomas ; Waertel, G ; Schminke, L

This case of a patient with Erdheim-Chester disease highlights the problems in diagnosing this very rare, largely unknown, but highly inflammatory non-Langerhans histiocytosis. This disease shows some characteristic clinical and molecular features including the BRAF V600E mutation, which was also demonstrated in this case in a perirenal tissue biopsy. The patient's condition improved under treatment with peginterferon alfa-2a and anakinra. However, remission for what is now 3 years was only achieved with the combination of anakinra and the BRAF inhibitor dabrafenib.

01 Feb 2026·United European Gastroenterology Journal

Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy

Article

Author: Demir, Münevver ; Akarca, Ulus S. ; Caruntu, Florin Alexandru ; Bock, Hans H. ; Yurdaydin, Cihan ; Gürel, Selim ; Wedemeyer, Heiner ; Sprinzl, Kathrin ; Wranke, Anika ; Keskin, Onur ; Papatheodoridis, George V. ; Cornberg, Markus ; Idilman, Ramazan ; Yalcin, Kendal ; Hardtke, Svenja ; Bockmann, Jan‐Hendrik ; Kahlhöfer, Julia ; Merle, Uta

ABSTRACT:

Background:

Chronic delta hepatitis represents a major health burden. Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). The aim of this study was to evaluate 10‐year long‐term clinical and virological outcomes after 96 weeks of treatment with PEG‐IFNα with or without tenofovir disoproxil fumarate (TDF).

Methods:

We conducted a retrospective follow‐up study of the Hep‐Net‐International‐Delta‐Hepatitis‐Intervention‐Study 2 (HIDIT‐II trial). Patients had received 96 weeks of treatment with either PEG‐IFNα‐2a plus TDF or PEG‐IFNα‐2a alone. Patients were included if they had completed the 96‐week treatment period and had at least one follow‐up visit (PEG‐IFNα‐2a + TDF; n = 51, PEG‐IFNα‐2a alone; n = 56).

Results:

Patients who received PEG‐IFNα‐2a + TDF were younger (37 vs. 42 years) and no significant differences were observed in other baseline characteristics between the two treatment arms. A total of 26 patients (24%) developed one or more liver‐related endpoints after a mean time of 8.4 years. The incidence of endpoints was significantly lower in the combination group (14% vs. 34%, p = 0.02). The development of liver‐related endpoints was also associated with non‐response to therapy (HDV RNA and HBsAg), elevated HBV DNA at week 72, and baseline age, cirrhosis, platelets, INR, AST, GGT, bilirubin and albumin according to the Cox regression model.

Conclusions:

The long‐term follow‐up of this large randomised clinical trial demonstrates that combination therapy with TDF and virological response to PEG‐IFNα‐2a (undetectable HDV RNA and HBsAg loss) were associated with better clinical outcomes.

Trial Registration:

NCT00932971, EudraCT 2008‐005560‐13

News (Medical) associated with Peginterferon alfa-2a

07 Oct 2025

·www.globenewswire.com

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that three abstracts featuring imdusiran data and one abstract featuring AB-101 data, have been accepted for poster presentations at the American Association for the Study of Liver Diseases (“AASLD”) – The Liver Meeting 2025, taking place November 7–11 in Washington, DC. Notably, the AB-101 abstract has been selected as a Poster of Distinction. Regular Abstracts Accepted as Poster Presentations: Publication Number: 1160Presentation Title: Imdusiran (AB-729) is safe and well-tolerated after repeat dosing in chronic hepatitis B patients: An integrated safety analysis of Phase 1 and 2 imdusiran clinical trialsPresenter: Tilly Varughese, MD, Medical Director, Clinical Development, Arbutus BiopharmaDate and Time: November 7, 2025, 8:00 am - 5:00 pm ETKey Findings: Imdusiran therapy in patients with chronic hepatitis B virus (“cHBV”) was safe and well tolerated when administered at both 60 mg and 90 mg dose levels every 8 weeks for 4 – 6 doses (24 – 48 weeks) and through up to 48 weeks of follow up after imdusiran dosing. Publication Number: 1244Presentation Title: IM-PROVE I: Hepatitis B virus (“HBV”) genotype responsiveness to pegylated interferon alfa-2a may be enhanced with imdusiran combination treatmentPresenter: Emily Thi, Senior Director, Immunobiology and Biomarkers Research, Arbutus BiopharmaDate and Time: November 7, 2025, 8:00 am - 5:00 pm ETKey Findings: In this limited dataset, the majority of subjects who achieved HBsAg response during pegylated interferon alfa-2a (“IFN”) treatment with or following imdusiran dosing were genotype B or C. These findings contrast with historical data from IFN therapy and suggest that imdusiran may enhance IFN responsiveness in cHBV patients with specific HBV genotypes. Further studies in larger cohorts are warranted to confirm these observations. Publication Number: 1184Presentation Title: Elevated soluble immune biomarkers in subjects with HBsAg loss after treatment with imdusiran and immunotherapeutic agents in the IM-PROVE I and IM-PROVE II studies Presenter: Emily Thi, Senior Director, Immunobiology and Biomarkers Research, Arbutus BiopharmaDate and Time: November 7, 2025, 8:00 am - 5:00 pm ETKey Findings: Imdusiran treatment is associated with increases in soluble immune biomarkers in both IM-PROVE I and IM-PROVE II studies. In subjects who lost HBsAg and had anti-HBs antibodies, a greater breadth and magnitude of immune biomarker increases were observed in IM-PROVE I subjects compared to IM-PROVE II. In both studies, subjects who showed increases in soluble immune biomarkers on-treatment met nucleos(t)ide analogue (“NA”) therapy discontinuation criteria and had baseline HBsAg ≤1000 IU/mL. Poster of DistinctionPublication Number: 1123Presentation Title: Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AB-101, a small-molecule PD-L1 inhibitor, in chronic hepatitis B patientsPresenter: Tilly Varughese, MD, Medical Director, Clinical Development, Arbutus BiopharmaDate and Time: November 7, 2025, 8:00 am - 5:00 pm ET. The poster will remain available for the full duration of the conference.Key Findings: Oral doses of AB-101 up to 30 mg QD for 28 days were generally well tolerated in NA-suppressed cHBV patients. Preliminary interim pharmacodynamic data indicate dose-related increases in PD-L1 receptor occupancy, with 83% mean maximal receptor occupancy at the 30 mg dose. Cohort 3B is ongoing and all available data, including safety, PK, receptor occupancy and HBV biomarkers, will be presented. The regular accepted abstracts are available to the public on the AASLD website and will be published in the October supplement of HEPATOLOGY. The poster presentations will be available on the AASLD website beginning November 7, 2025 at 8:00 am ET and will also be found on Arbutus’ website in the Publications section at https://www.arbutusbio.com/publications/. About Imdusiran (AB-729) Imdusiran is an RNAi therapeutic specifically designed to reduce all hepatitis B viral proteins and antigens including HBsAg, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to control the virus. Imdusiran targets hepatocytes using Arbutus’ novel covalently conjugated N-Acetylgalactosamine (“GalNAc”) delivery technology enabling subcutaneous delivery. To date, Arbutus has reported a total of eight patients with cHBV who have achieved a functional cure following treatment with imdusiran and NA therapy in combination with either IFN or low dose nivolumab plus an immunotherapeutic. Clinical data generated thus far has shown imdusiran to be generally safe and well-tolerated, while also providing meaningful reductions in HBsAg and hepatitis B virus DNA. About AB-101 AB-101 is an oral PD-L1 inhibitor candidate that is designed to allow for controlled checkpoint blockade while minimizing the systemic safety issues typically seen with checkpoint antibody therapies. Immune checkpoints such as PD-1/PD-L1 play an important role in the induction and maintenance of immune tolerance and in T-cell activation, for example against HBV. In Arbutus’ ongoing Phase 1a/1b clinical trial, AB-101 has been generally safe and well-tolerated with evidence of high receptor occupancy. About HBV Hepatitis B is a potentially life-threatening liver infection caused by HBV. HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. cHBV infection represents a significant unmet medical need. The World Health Organization estimates that over 250 million people worldwide suffer from cHBV infection, while other estimates indicate that approximately 2 million people in the United States suffer from cHBV infection. Approximately 1.1 million people die every year from complications related to cHBV infection despite the availability of effective vaccines and current treatment options. About Arbutus Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is currently developing imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101) for the treatment of cHBV infection. The Company is also consulting closely with and supporting its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of on-going lawsuits against Moderna and Pfizer/BioNTech for use of Arbutus’s patented LNP technology in their COVID-19 vaccines. For more information, visit www.arbutusbio.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include statements about: the potential to lead to a functional cure for HBV; the potential for Arbutus’ product candidates to achieve success in clinical trials; and Arbutus’ pipeline and development plans for its cHBV programs. With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: ongoing and anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ product candidates; economic and market conditions may worsen; and market shifts may require a change in strategic focus. A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law. Contact: Arbutus Biopharma Corporation / ir@arbutusbio.com

Clinical ResultVaccineClinical StudyImmunotherapy

19 Sep 2025

·www.prnewswire.com

AusperBio Completes Enrollment in Two Phase II Clinical Trials of AHB-137 for Chronic Hepatitis B

SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted oligonucleotide therapies for chronic hepatitis B (CHB) functional cure, today announced the completion of patient enrollment in two Phase II clinical trials evaluating its lead candidate, AHB-137, in patients with chronic hepatitis B ( CHB), marking an important milestone in the clinical development program. The Phase II study AB-10-8007 (NCT07069569) is a randomized, open-label, multicenter study to evaluate the efficacy and safety of AHB-137 Injection in combination with either a hepatitis B vaccine or pegylated interferon α-2b (Peg-IFN) in participants with HBeAg-negative CHB receiving nucleos(t)ide analogue (NA) therapy. The Phase II study AB-10-8008 (NCT06829329) is a randomized, multicenter study to evaluate the efficacy and safety of AHB-137 Injection in treatment-naïve participants with CHB. "Combination therapies have historically been a key to treat or cure chronic viral infections, including HIV and HCV." said Dr. Guofeng Cheng, Co-founder and CEO of AusperBio. "The AB-10-8007 study aims to combine AHB-137 with approved HBV treatments to further increase functional cure rates, while the AB-10-8008 study explores the potential to expand AHB-137 treatment to a broader patient population. Together, these studies could further establish AHB-137 as the potential backbone therapy for HBV functional cure. We look forward to sharing interim results at international conferences throughout 2026." "We are deeply grateful to the patients, investigators, site teams, and our AusperBio colleagues for their dedication and contributions to reaching this important milestone," said Dr. Chris Yang, Co-founder and CSO of AusperBio. "The completion of enrollment in these Phase II trials positions us well as we move into the pivotal Phase III study of AHB-137, which was recently approved in China. We are excited and committed to advancing new treatment options with the goal of bringing a functional cure to a broader population of patients living with HBV." About AHB-137 AHB-137, a novel unconjugated antisense oligonucleotide ( ASO) designed using AusperBio's proprietary Med-Oligo™ ASO technology platform and an investigational medicine, is being developed to achieve a functional cure for chronic hepatitis B. Its clinical development has generated promising data, with key preclinical and clinical results presented at global leading conferences including EASL (2023, 2024, 2025), AASLD (2024), and APASL (2025). This novel dual-mechanism ASO has completed its global Phase 1 trial and is currently advancing through multiple Phase 2 trials and a phase 3 trial in China. Supported by a clear global development strategy, AHB-137 is progressing rapidly toward delivering a potential cure for HBV. About AusperBio. AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on achieving functional cure for chronic hepatitis B infection. The company has developed a proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. For further information, please contact: Media Contact Email: [email protected] Investor Relations Contact: Tel: 650-888-1756 (US) Email: [email protected] SOURCE AusperBio Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2OligonucleotidePhase 3Phase 1Vaccine

28 Jul 2025

·www.einpresswire.com

Virion Therapeutics Provides Update on its VRON-0200 Clinical Development Program for HBV Functional Cure on World Hepatitis Day 2025

This “Spark and Fan” treatment strategy could potentially offer a simple and well tolerated solution for a wide range of future HBV functional cure regimens for patients worldwide.” — Dr. Sue Currie, COO, Virion PHILADELPHIA, PA, UNITED STATES, July 28, 2025 / EINPresswire.com / -- Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize first-in-class checkpoint modifiers, today, on World Hepatitis Day, provided a corporate update highlighting continued progress across its functional cure program for chronic hepatitis B virus (CHB). KEY PROGRAM HIGHLIGHTS o VRON-0200’s Phase 1b program is fully enrolled, with 34 CHB patients now treated with VRON-0200, including a combination cohort with investigational antivirals; longer term clinical data from the full cohort is expected in Q4 2025 o VRON-0200 clinical data, presented earlier this year at APASL and EASL demonstrated: - VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events (SAEs), treatment discontinuations, or treatment-related clinical laboratory abnormalities reported - HBsAg declines were observed in patients treated with an intramuscular (IM) injection of VRON-0200 even though VRON-0200 does NOT directly target S-antigen, suggesting a possible broadening, and restoration of anti-HBV immune responses - After a single VRON-0200 prime dose, rapid and profound HBsAg declines were observed in all evaluable patients 7 days after the first combination dose. These types of responses have not been previously reported, even with PEG-IFN containing regimens - These data suggest VRON-0200 could be the key backbone agent in future HBV functional cure regimens o The Phase 1b study is ongoing – these data, from all Cohorts, as well as the long-term followup and exploratory analyses, will further inform future treatment strategies to maximize functional cure rates and potentially expand patient populations o A global Phase 2b study (“SPARK-B”) for HBV Functional Cure is in development; in parallel, additional manufacturing activities to support late-stage development are ongoing o Virion is in partnership discussions to further accelerate development and maximize access to a potential functional cure for persons living with CHB worldwide “Despite a preventative HBV vaccine, CHB remains a widespread global problem affecting 254 million persons and contributing to 1.1 million deaths/year from liver related complications. On this World Hepatitis Day, Virion, along with its partners, are committed to finding a cure for CHB,” said Dr. Andrew D. Luber, CEO of Virion. Luber added, “It is exciting to see the VRON-0200 Phase 1b data support our “Spark and Fan” treatment model, with VRON-0200 “sparking” a new HBV-specific immune response, and then the “fanning” of this response with the addition of antivirals, which remove the virus and it’s immunosuppressive effects.” Dr. Sue Currie, Virion’s COO commented, “This “Spark and Fan” treatment strategy could potentially offer a simple and well tolerated solution for a wide range of future HBV functional cure regimens for patients worldwide. We are excited to continue our current VRON-0200 clinical development program, including the planning of our future SPARK-B Phase 2b clinical trial. On this World Hepatitis Day, we are aware of the burden of CHB, and the urgent unmet medical need to achieve a functional cure that is safe, convenient, effective, and accessible for persons worldwide. What makes VRON-0200 so promising, besides being the first new immune modulator to restore broad anti-HBV immunity since pegylated-interferon, is its ease of dosing (a single i.m. injection), and favorable safety and tolerability profile, all critical factors to future functional cure treatments for persons with CHB.” ABOUT CHRONIC HEPATITIS B Despite a preventative vaccine, cases of chronic hepatitis B (HBV) continue to rise, with an estimated 254 million persons infected worldwide and 1.1 million deaths per year from HBV-related liver complications. Chronic HBV remains a global health issue with a high unmet medical need since there is no cure available. The current standard of care requires lifelong antiviral therapy to maintain control of the virus. To learn more about hepatitis and World Hepatitis Day, visit: www.worldhepatitis.org ABOUT VRON-0200 VRON-0200 is a therapeutic immunotherapy, administered by intramuscular injection, designed with the goal of providing a functional cure for chronic HBV infection. While the virus itself stimulates HBV-specific CD8+ T cells, for those patients that can’t clear the initial infection, their T cells soon become exhausted, placing limits on their ability to proliferate and control the virus. An ongoing Phase 1b trial has shown VRON-0200 to be safe, well tolerated, immunogenic, and has anti-HBV activity in chronically HBV-infected patients on nucleos(t)ide therapy. More details of the study can be found at ClinicalTrials.gov (Identifier: NCT06070051). ABOUT VIRION THERAPEUTICS (VIRION) Virion Therapeutics, LLC is a clinical-stage company developing novel T cell-based immunotherapies to cure cancer and chronic infectious diseases that utilize proprietary genetically encoded checkpoint modifiers to enhance and broaden CD8+ T cell responses to a tumor or chronic infection. Virion has since developed a robust pipeline, including its lead VRON-0200 clinical program, and several additional IND-enabling programs, such as its VRON-0300 oncology program for advanced solid tumors, leveraging its proprietary platform technologies. To learn more, visit www.VirionTx.com Sue Currie, PhD Virion Therapeutics, LLC scurrie@viriontx.com Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2ImmunotherapyPhase 1Clinical Result

100 Deals associated with Peginterferon alfa-2a

External Link

KEGG	Wiki	ATC	Drug Bank
D02747	Peginterferon alfa-2a	L03AB11	DB00008

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B	Japan	Chugai Pharmaceutical Co., Ltd.	16 Oct 2003
Hepatitis C	Japan	Chugai Pharmaceutical Co., Ltd.	16 Oct 2003
Hepatitis B, Chronic	European Union	Pharma& Schweiz GmbH	20 Jun 2002
Hepatitis B, Chronic	Iceland	Pharma& Schweiz GmbH	20 Jun 2002
Hepatitis B, Chronic	Liechtenstein	Pharma& Schweiz GmbH	20 Jun 2002
Hepatitis B, Chronic	Norway	Pharma& Schweiz GmbH	20 Jun 2002
Hepatitis C, Chronic	European Union	Pharma& Schweiz GmbH	20 Jun 2002
Hepatitis C, Chronic	Iceland	Pharma& Schweiz GmbH	20 Jun 2002
Hepatitis C, Chronic	Liechtenstein	Pharma& Schweiz GmbH	20 Jun 2002
Hepatitis C, Chronic	Norway	Pharma& Schweiz GmbH	20 Jun 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polycythemia Vera	NDA/BLA	European Union	Pharma& Schweiz GmbH	27 Jun 2024
Thrombocythemia, Essential	NDA/BLA	European Union	Pharma& Schweiz GmbH	27 Jun 2024
Staphylococcal Scalded Skin Syndrome	Phase 3	United Kingdom	-	22 Sep 2011
Chronic hepatitis C genotype 3	Phase 3	Austria	-	07 Mar 2008
Chronic hepatitis C genotype 1	Phase 3	Hungary	Hoffmann-La Roche, Inc.	01 Jun 2006
Compensated cirrhosis	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	01 Jun 2006
Pseudohyperkalemia Cardiff	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	01 Jun 2006
Liver Injury	Phase 3	United Kingdom	-	27 Apr 2006
Hepatitis D, Chronic	Phase 3	Romania	Hoffmann-La Roche, Inc.	01 Oct 2005
Complete atrioventricular block	Phase 3	Italy	Roche Holding AG	12 Apr 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01718301 (BOC-HIV, CTgov)	Phase 3	Chronic hepatitis C genotype 1 \| Coinfection \| HIV Infections ... View more	108	Peginterferon alfa-2a+boceprevir+Peginterferon alfa-2b+Ribavirin	znjbonkvva = dotihgdvvc kcdkkleuor (hqoqfdzxrd, efdquulheq - vfjigabtum) View more	-	24 Aug 2025
ASH2024	Not Applicable	-	-	Peginterferon alpha-2a 180 mcg	kiqficqslh(hhwpmjijdr) = grade 1-2 fatigue and cytopenias in 71.4%, G4 neutropenia in 14.3%, G4 febrile neutropenia with sepsis in 14.3% msxrigndsa (govuxaexru ) View more	-	08 Dec 2024
				Bictegravir/Emtricitabine/Tenofovir alafenamide (Biktarvy)
1807 (ASH2024)	Phase 2	Polycythemia Vera \| Thrombocythemia, Essential JAK2+ \| CALR \| MPL ... View more	-	PEG-IFN in Essential Thrombocytopenia	newtdftcnm(qhpjyyxfck) = juqophqwmz khiaxdelzx (dzooyewvls )	Positive	07 Dec 2024
Tandem Meetings ASTCT and CIBMTR2024 Manual	Not Applicable	Hematopoietic stem cell transplantation	12	Peginterferon-alpha (pegIFNα) 180 mcg	fipbcqukhx(snxfvshfqt) = ulasevpeen oizjmxpori (xnbakojzkx, 58.7 - 100) View more	Positive	01 Feb 2024
NCT00932971 (HIDIT-II, Pubmed \| Liver Int)	Phase 2	Hepatitis D	-	PEG-IFNa + TDF	igsgtaijws(twuigmplec) = nekcwhhsns whabstnkac (krofikssdv ) View more	Positive	01 Jan 2024
				PEG-IFNa + placebo	wdskleznyz(enxsgshrgf) = siuyjtuczl ekpiksnbpt (nemzcfolvq ) View more
NCT01369212 (Pubmed \| Am J Gastroenterol)	Not Applicable	Hepatitis B, Chronic	201	Tenofovir disoproxil fumarate (TDF) + Peginterferon (PegIFN) alfa-2a	ospqfvawqi(fcumzfgltx) = bmjijvmkwg xwfywleehw (xvzvtbybmd )	-	05 Jan 2023
				Tenofovir disoproxil fumarate (TDF) alone	ospqfvawqi(fcumzfgltx) = jahdpdogmv xwfywleehw (xvzvtbybmd )
NCT01369212 (HBRN \| Hepatitis B Research Network Immune-Active Trial, CTgov)	Phase 3	Hepatitis B, Chronic	201	Tenofovir (Tenofovir)	ggtkrdnjgd = cdoyicwttj faumeyttyl (cbcndkuzga, jhzititmsg - zxgyhcpibu) View more	-	12 Oct 2022
				tenofovir+Pegasys (Peginterferon-alfa 2a and Tenofovir)	ggtkrdnjgd = utnsmyscvp faumeyttyl (cbcndkuzga, ftupppubnb - zroevwbomm) View more
NCT01769833 (Pubmed \| PLoS One)	Phase 3	Hepatitis B, Chronic Maintenance	149	PegIFN alfa-2a	kvonltdkex(yfuzibashd) = plsnsicbwx yfjlukpriu (xdydkwrdbv ) View more	-	01 Jan 2022
				Nucleos(t)ide analogue	kvonltdkex(yfuzibashd) = nkvuljawab yfjlukpriu (xdydkwrdbv ) View more
NCT02328755 (CTgov)	Phase 1/2	Acute Myeloid Leukemia	37	Hematopoietic Cell Transplant (HCT)+peg-IFN-α+Tacrolimus+Methotrexate	kraqwfbhen = dcpisvierw masedhufyz (xmtwemerxe, rqbllredhi - xaxaikuapx) View more	-	06 Oct 2021
NCT02328755 (Pubmed \| Blood Adv)	Phase 1/2	Relapsing acute myeloid leukemia	37	pegIFNα	wvzfdhvbbf(aknyyadyud) = bsliamefit oveegaybts (wausfglgah ) View more	-	04 Oct 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis